NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Monday that its revenues for 2013 more than doubled year over year.

The microRNA-based diagnostics firm said that revenues last year increased to $405,000 from $201,000 in 2012 as commercial activities and investments in its commercial infrastructure ticked up.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.